98%
921
2 minutes
20
Urinary complications resulting from benign prostatic hyperplasia and bladder outlet obstruction continue to be a serious health problem. Novel animal model systems and imaging approaches are needed to understand the mechanisms of disease initiation, and to develop novel therapies for benign prostatic hyperplasia. Long-term administration of both estradiol and testosterone in mice can result in prostatic enlargement and recapitulate several clinical components of lower urinary tract symptoms. Herein, we use longitudinal magnetic resonance imaging and histological analyses to quantify changes in prostatic volume, urethral volume, and genitourinary vascularization over time in response to estradiol-induced prostatic enlargement. Our data demonstrate significant prostatic enlargement by 12 weeks after treatment, with no detectable immune infiltration by macrophages or T- or B-cell populations. Importantly, the percentage of cell death, as measured by terminal deoxynucleotidyl transferase dUTP nick-end labeling, was significantly decreased in the prostatic epithelium of treated animals as compared to controls. We found no significant change in prostate cell proliferation in treated mice when compared to controls. These studies highlight the utility of magnetic resonance imaging to quantify changes in prostatic and urethral volumes over time. In conjunction with histological analyses, this approach has the high potential to enable mechanistic studies of initiation and progression of clinically relevant lower urinary tract symptoms. In addition, this model is tractable for investigation and testing of therapeutic interventions to ameliorate or potentially reverse prostatic enlargement.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762949 | PMC |
http://dx.doi.org/10.1016/j.ajpath.2017.07.014 | DOI Listing |
IJU Case Rep
September 2025
Introduction: The diagnosis of systemic transthyretin amyloidosis based on prostate biopsy is very rare, and we report this case with a literature review.
Case Presentation: A 73-year-old male patient was referred to our department due to an increased serum prostate-specific antigen level at 10.4 ng/mL while receiving benign prostatic hypertrophy treatment.
World J Urol
September 2025
Urology Department - Frimley Park Hospital NHS Foundation Trust, Portsmouth Road, Frimley, Camberley, GU16 7UJ, England.
Purpose: The influence of a previous Urolift treatment on the outcomes of prostate Aquablation is still controversial. This retrospective cohort study aimed to evaluate the perioperative outcomes, efficacy, feasibility, and safety of Aquablation after previous Urolift treatment.
Methods: The charts of patients with benign prostate hyperplasia (BPH) complicated by storage and voiding symptoms, who were previously treated with Urolift followed by Aquablation between January 2022 and July 2024, were retrospectively reviewed and analyzed for changes in International Prostate Symptom Score (IPSS), maximum urinary flow rates (Qmax), and postvoid residual volume (PVR) from baseline (pre-Aquablation) to the mean of three months postoperatively.
Scand J Urol
September 2025
Boston Scientific Corporation, Marlborough, MA, USA.
Objectives: This capacity and budget impact analysis considers implications of offering a more diversified benign prostate enlargement (BPE) surgical care offering from a healthcare payer perspective in Sweden, Denmark, Norway and Finland.
Methods: A cohort simulation model compares 4-year treatment costs and capacity impact, including hospital bed-days and operating time, with Transurethral Resection of the Prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP) using MOSES™Technology, photoselective vaporisation of the prostate (PVP) and Rezūm™ Water Vapour Therapy (WVTT). Current treatment choice is compared to a hypothetical scenario, where TURP-proportion is reduced to 50% and volumes of HoLEP, PVP and WVTT are increased.
Medicine (Baltimore)
August 2025
Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Rationale: This study aims to highlight the diagnostic challenges and multidisciplinary management of pelvic lipomatosis (PL), emphasizing imaging's pivotal role and the need for early intervention to mitigate long-term morbidity. With fewer than 200 reported cases, PL remains underrecognized; this case underscores its potential to mimic common gastrointestinal/urinary disorders, advocating for heightened clinical suspicion.
Patient Concerns: A 42-year-old male presented with a 2-day history of colicky abdominal pain under the xiphoid process, ac companied by nausea, vomiting, and watery stools.
World J Urol
September 2025
Department of Urology, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei, 10002, Taiwan (R.O.C.).
Purpose: To characterize the learning process by comparing the clinical outcomes and learning curves of prostatic urethral lift (PUL) performed by experienced versus naïve urologists.
Methods: Consecutive patients treated with PUL at a tertiary center by an experienced urologist with > 100 PUL cases or by naïve urologists with no prior PUL experience were included in this study. Perioperative parameters, functional outcomes, complications, and retreatment rates were compared.